The off-target effects of torcetrapib.
Funder
John W
JW
Prince Henry's Institute of Medical Research, Clayton, Victoria 3168, Australia. john.funder@princehenrys.org
D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors; D008076:Cholesterol, HDL / Q000378:metabolism; D016503:Drug Delivery Systems / Q000009:adverse effects; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D006929:Hyperaldosteronism / Q000139:chemically induced / Q000401:mortality; D011804:Quinolines / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology*; D014883:Water-Electrolyte Imbalance / Q000139:chemically induced / Q000401:mortality
D000924:Anticholesteremic Agents; C506642:CETP protein, human; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D011804:Quinolines; C483909:torcetrapib